-+ 0.00%
-+ 0.00%
-+ 0.00%

MiMedx to buy Sanara MedTech in USD 350 million cash-and-stock deal

PUBT·07/29/2026 20:06:31
Listen to the news
MiMedx to buy Sanara MedTech in USD 350 million cash-and-stock deal
  • MiMedx agreed to buy Sanara MedTech in a cash-and-stock deal valuing Sanara at USD 35 a share, or about USD 350 million enterprise value.
  • Sanara holders will receive USD 33 in cash plus 0.4735 MiMedx shares per share, based on a USD 4.22 reference price.
  • MiMedx expects to fund the cash portion with cash on hand plus a new USD 300 million term loan from Hayfin Capital Management.
  • The companies expect more than USD 20 million of run-rate cost synergies; MiMedx projects 2027 revenue above USD 400 million with adjusted EBITDA margin over 20%.
  • Closing is targeted by year-end, pending Sanara shareholder vote and required regulatory clearances.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MiMedx Group Inc. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.